期刊文献+

皮下注射甘精胰岛素对初次诊断的2型糖尿病患者糖脂代谢、胰岛素测定的影响 被引量:2

The effect of therapy with glargine on glucolipid metabolism and insulin detection in newly diagnosed type 2 diabetic patients
下载PDF
导出
摘要 目的:探讨甘精胰岛素对门诊初诊的2型糖尿病(type 2 diabetes mellitus,T2DM)患者糖脂代谢、胰岛B细胞功能、胰岛素测定的影响。方法:32例初诊T2DM患者,给予甘精胰岛素每晚定时皮下注射1次,剂量为0.2~1.0 U/(kg.d),治疗3个月后观察体重、血糖、血脂、血压、胰岛素抵抗指数、胰岛素分泌指数的变化。结果:3个月后患者血糖、血脂、血压、糖化血红蛋白(HbA1c)均显著降低,差异有统计学意义(P<0.05);治疗前后体重没有明显变化,甘精胰岛素使用后,胰岛素分泌曲线较前上升,且口服葡萄糖耐量试验(OGTT)后呈典型的胰岛素分泌曲线,即治疗后胰岛素分泌指数显著增加,胰岛素抵抗指数显著改善,胰岛素早期相分泌前移,差异均有统计学意义(P<0.05或P<0.01),且治疗后胰岛素分泌曲线及高峰与C-肽一致。结论:甘精胰岛素短期内可有效改善患者的血糖、血脂、血压水平及胰岛细胞分泌功能,且不影响糖耐量试验下胰岛素分泌的检测,提示血浆检测胰岛素与甘精胰岛素具有不同的免疫原性。 Objective:To evaluate the therapy effects of glargine on glucolipid metabolism and B-cell function,insulin detection in newly diagnosed type 2 diabetes mellitus(T2DM) patients.Methods:Thirty-two cases of newly diagonosed T2DM,were treated with subcutaneous injection of glargine at fixed time everyday.Fasting serum glucose,blood lipid,blood pressure,the HOMA-IR were detected and compared after three months treatment.Results:After three months treatment,blood lipid,blood pressure,blood glucose,glycohemoglobin A1c(HbA1c) were significantly lower,the bodyweight had no signifancanct difference compare with the un-treatment group;the level of the HOMA-B were significantly higher after treatment;the HOMA-IR were significantly lower(P 〈 0.01).Conclusion: Glargine can effectively improve,control serum glucose,blood lipid,blood pressure,and the glaginetreatment did not influence the detection of insulin.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2011年第6期864-866,共3页 Journal of Nanjing Medical University(Natural Sciences)
基金 江苏省卫生厅创新基金(XK12200903)
关键词 甘精胰岛素 血脂 血压 胰岛功能 glargine insulin blood lipid blood pressure beta-cell function of insulin
  • 相关文献

参考文献3

二级参考文献15

  • 1Sivitz MJ,Reeves GD.Continous subcutaneous insulin infusion:a comprehensive review of insulin pump therapy.Arch Inten Med,2001,161:2293-2300.
  • 2Rachman J,Paype MJ,Levy JC,et al.Changes in amylin and amylinlike peptide concentration andbeta cell function in response to sulfonylurea or insulin therapy in NIDDM.Diabetes Care,1998,21:810-816.
  • 3Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use[J]. Diabetes, 2000, 49(6):999-1005.
  • 4Rakatzi I, Seipke G, Eckel J. [LysB3,GluB29 ]insulin:a novel insulin analog with enhanced b cell protective action [J]. Biochem Biophys Res Commun, 2003, 310(3):852-59.
  • 5Zhou YP, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle[J]. J Clin Invest, 1994, 93(2):870-76.
  • 6Gerich JE. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2diabetes mellitus [J]. Mayo Clin Proc, 2003, 78(4):447-56.
  • 7Kahn SE. The importance of the β-cell in the pathogenesis of type 2 diabetes mellitus [J]. Am J Med,2000, 108(suppl 6a):2S-8S.
  • 8Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes [J]. Diabetes, 2003, 52(1):102-10.
  • 9Butler AE, Janson J, Soeller WC, et al. Increased beta-cell apoptosis prevents adaptive increase in betacell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid [J]. Diabetes, 2003, 52(9):2304-14.
  • 10Mandrup-Poulsen T. Apoptotic signal transduction pathways in diabetes [J]. Biochem Pharmacol, 2003, 66(8): 1433-40.

共引文献85

同被引文献17

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部